Breaking News Instant updates and real-time market news.

DDD

3D Systems

$12.05

0.01 (0.08%)

, ABT

Abbott

$63.60

1.73 (2.80%)

04:55
03/10/18
03/10
04:55
03/10/18
04:55

American Academy of Orthopaedic Surgeons to hold annual meeting

AAOS 2018 Annual Meeting to be held in New Orleans, LA on March 6-10.

DDD

3D Systems

$12.05

0.01 (0.08%)

ABT

Abbott

$63.60

1.73 (2.80%)

ANIK

Anika Therapeutics

$53.49

0.06 (0.11%)

ATHN

Athenahealth

$147.85

3 (2.07%)

GMED

Globus Medical

$51.28

0.65 (1.28%)

FLXN

Flexion

$26.73

-0.28 (-1.04%)

EXAC

Taken private 2/18

$49.25

(0.00%)

OFIX

Orthofix

$59.32

1.39 (2.40%)

OMI

Owens & Minor

$17.03

0.22 (1.31%)

PCRX

Pacira

$31.90

0.2 (0.63%)

RDUS

Radius Health

$35.28

2.23 (6.75%)

COF

Capital One

$100.79

2.64 (2.69%)

CAH

Cardinal Health

$71.16

0.74 (1.05%)

SNN

Smith & Nephew

$37.53

0.29 (0.78%)

SNE

Sony

$51.40

0.12 (0.23%)

MDT

Medtronic

$83.15

0.94 (1.14%)

CNMD

CONMED

$63.31

1.15 (1.85%)

ENDP

Endo

$6.98

-0.1 (-1.41%)

MDXG

MiMedx

$7.42

-0.5 (-6.31%)

WMGI

Wright Medical

$20.67

0.13 (0.63%)

VCEL

Vericel

$11.55

-0.25 (-2.12%)

  • 12

    Mar

  • 13

    Mar

  • 14

    Mar

  • 14

    Mar

  • 15

    Mar

  • 21

    Mar

  • 23

    Mar

  • 23

    Mar

  • 03

    Apr

  • 06

    Apr

  • 30

    May

DDD 3D Systems
$12.05

0.01 (0.08%)

02/09/18
JPMS
02/09/18
DOWNGRADE
Target $11
JPMS
Underweight
JPMorgan downgrades 3D Systems to Underweight after 14% year-to-date rally
JPMorgan analyst Paul Coster downgraded 3D Systems to Underweight from Neutral with the shares up 14% year-to-date. The current multiple prices in a return to growth that will prove premature, Coster tells investors in a research note. He expects 3D Systems will underperform the mean of his coverage over the next 6-12 months, but does not view the stock as a good short. The analyst keeps an $11 price target on the shares. 3D Systems closed yesterday down 50c to $9.82.
11/20/17
PIPR
11/20/17
UPGRADE
Target $6.25
PIPR
Neutral
3D Systems upgraded to Neutral from Underweight at Piper Jaffray
Piper Jaffray analyst Troy Jensen upgraded 3D Systems to Neutral saying he sees limited downside from current share levels. The stock now trades below the group average and at the lowest valuation in the sector, Jensen tells investors in a research note. The analyst, however, says his opinion regarding intensifying competition against 3D Systems hasn't changed. He still believes the next six months "will still be a struggle" for the company. Jensen keeps a $6.25 price target for the shares. 3D Systems closed Friday up 1c to $8.34.
11/20/17
11/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Verizon (VZ) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jennifer Fritzsche saying after dropping 16% since mid-January, "much of the bad news is behind the stock" in terms of wireless service revenue declines. 2. 3D Systems (DDD) upgraded to Neutral from Underweight at Piper Jaffray with analyst Troy Jensen saying he sees limited downside from current share levels. 3. Viacom (VIAB, VIA) upgraded to Hold from Sell at Deutsche Bank with analyst Bryan Kraft saying he sees limited room for further multiple compression. 4. Maxwell (MXWL) upgraded to Buy from Neutral at Roth Capital with analyst Craig Irwin saying he sees consensus estimates as achievable for 2018, and merger synergies with NessCap should start making a more material contribution over the next few quarters. 5. National Beverage (FIZZ) upgraded to Positive from Neutral at Susquehanna with analyst Pablo Zuanic citing his increased conviction on the sales and bottom-line upside of the company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/09/18
JPMS
02/09/18
DOWNGRADE
Target $11
JPMS
Underweight
3D Systems downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Paul Coster downgraded 3D Systems to Underweight with an $11 price target.
ABT Abbott
$63.60

1.73 (2.80%)

02/27/18
JPMS
02/27/18
NO CHANGE
JPMS
Abbott's strong Libre launch supports cautious Dexcom stance, says JPMorgan
Abbott's Libre launch is off to a strong start in the U.S. with more than 25,000 patients having started on the device since the launch in early December, JPMorgan analyst Michael Weinstein tells investors in a research note. It remains way too early, however, to say what percent of patients will stick with the device, the analyst adds. The Libre launch reinforces the analyst's cautious stance on shares of Dexcom (DXCM). He expects Dexcom's growth to slow over the course of the year and for 2019 to prove "much more challenging" than 2018. Weinstein has an Overweight rating on Abbott and Neutral rating on Dexcom.
02/12/18
OPCO
02/12/18
NO CHANGE
Target $67
OPCO
Outperform
Dexcom price target lowered to $67 from $72 at Oppenheimer
Oppenheimer analyst Steven Lichtman lowered his price target for Dexcom (DXCM) to $67 from $72 on lowered estimates, while reiterating an Outperform rating on the stock. The analyst recently surveyed high-volume U.S. endocrinologists on the latest in continuous glucose monitoring now with Abbott's (ABT) Libre Flash on the market. According to respondents, there is some impact on Dexcom new prescriptions since Libre launch and some current Dexcom patients are interested in switching, but the impact looks within expectations, he contends. Overall, Lichtman believes the rollouts of Libre and Medtronic's (MDT) 670G remain overhangs on Dexcom near-term, but his survey suggests an environment no worse than guidance and conditions on the ground should change again in 2H18 with approval of Dexcom's next-generation G6.
01/30/18
ARGS
01/30/18
NO CHANGE
Target $80
ARGS
Buy
Abbott price target raised to $80 from $66 at Argus
Argus analyst David Toung raised his price target on Abbott to $80 and kept his Buy rating after strong Q4 top-line growth. Toung says the company's future expansion will be driven by the acquisitions of St. Jude Medical and Alere, as well as by the recent launch of new products, which merit a premium valuation.
02/28/18
LSCM
02/28/18
NO CHANGE
Target $38
LSCM
Buy
Surmodics price target raised to $38 from $35 at Lake Street
Lake Street analyst Brooks O'Neil raised his price target for Surmodics (SRDX) to $38 saying the company's strategic agreement with Abbott Laboratories (ABT) is a "game changer." The deal validates Surmodics' "whole products" strategy, and provides both a financial and strategic runway for SurVeil, O'Neil tells investors in a research note. He keeps a Buy rating on the shares.
ANIK Anika Therapeutics
$53.49

0.06 (0.11%)

12/28/17
BRRR
12/28/17
NO CHANGE
Target $57
BRRR
Outperform
Anika bone filler clearance another positive step, says Barrington
Barrington analyst Michael Petusky said he does not see Anika Therapeutics' HA-based bone void filler, which just received FDA clearance, to contribute materially to 2018 revenues, but he does view the clearance as another positive step in the company's path toward building out a meaningful regenerative medicine franchise. He keeps an Outperform rating and $57 price target on Anika shares.
01/24/18
FANA
01/24/18
UPGRADE
Target $68
FANA
Overweight
Anika Therapeutics upgraded to Overweight from Equal-Weight at First Analysis
First Analysis analyst Joseph Munda upgraded Anika Therapeutics to Overweight and raised his price target for the shares to $68 from $45. A meeting with management gives the analyst confidence that Anika can effectively commercialize products without having to use DePuy Mitek as a marketing partner. In addition to a "deep product pipeline, this osteoarthritis therapy leader has a strong margin profile," Munda tells investors in a research note.
02/23/18
BRRR
02/23/18
DOWNGRADE
BRRR
Market Perform
Anika downgraded to Market Perform from Outperform at Barrington
Barrington analyst Michael Petusky downgraded Anika Therapeutics to Market Perform saying the shares are near full value following the company's Q4 results. Anika's operating expenses will ramp meaningfully in 2018, reducing near-term profitability and likely capping the share price over the next few quarters, Petusky tells investors in a research note.
01/26/18
SIDC
01/26/18
INITIATION
SIDC
Buy
Anika Therapeutics initiated with a Buy at Sidoti
ATHN Athenahealth
$147.85

3 (2.07%)

02/27/18
BOFA
02/27/18
INITIATION
Target $147
BOFA
Neutral
athenahealth reinstated with a Neutral at BofA/Merrill
BofA/Merrill analyst Michael Cherny reinstated coverage on athenahealth with a Neutral and $147 price target.
01/19/18
01/19/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Becton Dickinson (BDX) reinstated with a Buy at BofA/Merrill. 2. athenahealth (ATHN) initiated with an In Line at Evercore ISI. 3. Corbus Pharmaceuticals (CRBP) initiated with an Outperform at Raymond James. 4. Trade Desk (TTD) initiated with a Buy at Stifel. 5. Intellipharmaceutics (IPCI) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/05/18
RHCO
02/05/18
NO CHANGE
Target $180
RHCO
Buy
athenahealth price target raised to $180 from $156 at SunTrust
SunTrust analyst Sandy Draper raised his price target on athenahealth to $180, citing the company's Q4 earnings beat as well as his expectations of maintaining double-digit topline growth and operating margin expansion to 20% by 2019. Draper also points to improved investor visibility after the company "scrubbed" its bookings reporting to make them "higher quality" than in the prior period. The analyst keeps his Buy rating on athenahealth.
02/08/18
PIPR
02/08/18
NO CHANGE
Target $154
PIPR
Overweight
Immelt joining significant milestone for athenahealth, says Piper Jaffray
Piper Jaffray analyst Sean Wieland calls the announcement of Jeff Immelt joining as chairman "one of the more significant milestones" of athenahealth. The entire healthcare system will take notice, Wieland tells investors in as research note. The analyst believes Immelt likely thinks he can help make athenahealth much bigger. Wieland keeps an Overweight rating on athenahealth with a $154 price target.
GMED Globus Medical
$51.28

0.65 (1.28%)

02/22/18
BTIG
02/22/18
NO CHANGE
Target $51
BTIG
Buy
Globus Medical price target raised to $51 from $45 at BTIG
BTIG analyst Ryan Zimmerman raised his price target on Globus Medical to $51, saying the company's Q4 earnings highlighted the momentum from the recent robotics launch. Zimmerman believes that the company's ability to grow its market share will depend on product innovation and expanding its salesforce, which he believes can be achieved with the reinvestment of the gains from U.S. tax changes. The analyst also keeps his Buy rating on Globus Medical, stating that while the upside in the core U.S. spine market growth is limited, the company can outperform from new product launches.
02/13/18
NEED
02/13/18
NO CHANGE
NEED
Needham a buyer of Medical Technologies product makers on Amazon headlines
After The Wall Street Journal report claiming that Amazon (AMZN) is attempting to become a major hospital supplier, Needham analyst Mike Matson said that he believes the e-commerce giant has typically disrupted middlemen much more than manufacturers. The analyst, who thinks Amazon's model may work for "lower tech" products but is unlikely to work with "higher tech" products, would be a buyer of Medical Technologies product maker stocks if they are down on weakness related to the headline risk represented by Amazon. However, Matson notes that he believe that Cantel Medical (CMD), CONMED (CNMD), Medtronic (MDT), Stryker (SYK) and Teleflex (TFX) generate a portion of their sales from "lower tech" products. Other stocks in MedTech manufacturing include AtriCure (ATRI), Cardiovascular Systems (CSII), Hill-Rom (HRC), K2M Group (KTWO), Mazor Robotics (MZOR), Zimmer Biomet (ZBH), Boston Scientific (BSX), Globus Medical (GMED), NuVasive (NUVA) and Wright Medical (WMGI).
02/22/18
ADAM
02/22/18
NO CHANGE
Target $53
ADAM
Buy
Globus Medical price target raised to $53 from $47 at Canaccord
Canaccord analyst Kyle Rose raised his price target on Globus Medical to $53 from $47 following solid Q4 results. The analyst cited continued share gains in the U.S. business, strong growth outside the U.S., and positive momentum in its Emerging Technologies segment. Rose reiterated his Buy rating on Globus Medical shares.
01/10/18
WELS
01/10/18
NO CHANGE
Target $51
WELS
Outperform
Globus Medical price target raised to $51 from $46 at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen raised his price target for Globus Medical to $51 from $46 following the company's preliminary Q4 results and 2018 financial outlook, both of which exceeded expectations. The analyst reiterates an Outperform rating on the shares.
FLXN Flexion
$26.73

-0.28 (-1.04%)

02/01/18
BREN
02/01/18
INITIATION
Target $42
BREN
Buy
Flexion initiated with a Buy at Berenberg
Berenberg analyst Patrick Trucchio initiated Flexion with a Buy and $42 price target.
10/27/17
RBCM
10/27/17
NO CHANGE
RBCM
Flexion shares at compelling entry point after 34% pullback, says RBC Capital
RBC Capital analyst Randall Stanicky reiterated an Outperform rating and $44 price target on Flexion, saying he sees the 34% pullback in Flexion shares this month ahead of the Zilretta launch as short term, given the company's solid funding of about $12 cash per share, its thematic positioning as an opioid alternative, and its inherent strategic value.
10/30/17
WELS
10/30/17
NO CHANGE
Target $39
WELS
Outperform
Survey suggests Flexion Zilretta will be 'a hit,' says Wells Fargo
Wells Fargo analyst David Maris notes that while Flexion shares have declined in recent weeks following the approval of Zilretta and its subsequent equity offering, he believes this decline is mainly due to lack of near-term news flow, not a change in fundamentals. Citing a survey of 25 orthopedic surgeons, the analyst says results are very consistent with previous physician surveys and doctor interviews, indicating "significant potential" for Zilretta. If Zilretta reaches 37% penetration in OA knee, as the survey results suggest, it would generate more than $1B in revenue, he contends. Maris reiterates an Outperform rating and $39 price target on the shares.
01/08/18
WELS
01/08/18
NO CHANGE
WELS
Outperform
Flexion repeat dosing data for Zilretta encouraging, says Wells Fargo
Wells Fargo analyst David Maris said he remains excited about Zilretta and its longer-term growth potential and he is encouraged by initial data from its Phase 3B trial evaluating repeat administration in patients with OA of the knee. Maris, who estimates Zilretta sales of approximately $196M in 2019, keeps an Outperform rating on Flexion shares.
EXAC Taken private 2/18
$49.25

(0.00%)

10/23/17
SIDC
10/23/17
DOWNGRADE
SIDC
Neutral
Exactech downgraded to Neutral from Buy at Sidoti
Exactech (EXAC) is being acquired by TPG for $42 per share in cash.
10/24/17
GABE
10/24/17
DOWNGRADE
GABE
Hold
Exactech downgraded to Hold from Buy at Gabelli
10/23/17
BARD
10/23/17
DOWNGRADE
BARD
Neutral
Exactech downgraded to Neutral from Outperform at Baird
Exactech (EXAC) is being acquired by TPG for $42 per share in cash.
OFIX Orthofix
$59.32

1.39 (2.40%)

05/23/17
RHCO
05/23/17
INITIATION
RHCO
Buy
Orthofix initiated with a Buy at SunTrust
SuinTrust analyst Bruce Nudell started coverage of Orthofix with a $49 price target and a Buy rating. The analyst says that the company has improved its "operational efficiency" and can use M&a to accelerate its growth and boost its stock multiple. He thinks the company will generate "modest" organic growth and steady margins going forward, excluding any M&A.
06/14/17
LTCO
06/14/17
INITIATION
Target $53.25
LTCO
Buy
Orthofix initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Jeffrey Cohen started Orthofix with a Buy rating and $53.25 price target.
06/20/17
BTIG
06/20/17
INITIATION
Target $52
BTIG
Buy
Orthofix initiated with a Buy at BTIG
BTIG analyst Ryan Zimmerman started Orthofix with a Buy rating and $52 price target, saying its strong gross margins and sizable EBITDA should result in strong free cash flow.
03/05/18
RHCO
03/05/18
NO CHANGE
Target $67
RHCO
Buy
Orthofix price target raised to $67 from $60 at SunTrust
SunTrust analyst Bruce Nudell raised his price target on Orthofix to $67 on modeled benefits of the company's effective corporate tax rate declining to about 30%. The analyst believes that the company will approach completion of its product portfolio refurbishment while also optimizing its sales footprint. Over the medium term, Nudell expects the company's bone stimulation business to grow at a mid-single digit range thanks to its strong insurance and sales infrastructure. The analyst keeps his Buy rating on Orthofix.
OMI Owens & Minor
$17.03

0.22 (1.31%)

12/19/17
JPMS
12/19/17
DOWNGRADE
Target $22
JPMS
Underweight
Owens & Minor downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Lisa Gill downgraded Owens & Minor to Underweight and cut her price target for the shares to $22 from $28. The analyst sees integration risk from the Halyard Health S&IP business acquisition and believes the Q3 miss presents concerns around management's 1%-3% organic top-line growth targets.
02/14/18
JEFF
02/14/18
NO CHANGE
JEFF
Amazon focusing on bolstering medical device distribution, says Jefferies
Yesterday's Wall Street Journal report and a recent scan of job postings still point to Amazon.com's (AMZN) focus on bolstering its medical device/supplies distribution capabilities, specifically targeting hospitals, Jefferies analyst Brian Tanquilut. These postings support a negative thesis for Cardinal Health (CAH), Owens & Minor (OMI) and Premier's (PINC) medical supplies businesses, the analyst adds. Further, he sees the news as an incremental positive for AmerisourceBergen (ABC), McKesson (MCK), CVS Health (CVS) and Walgreens Boots Alliance (WBA) since it further supports the view that Amazon isn't looking to enter the prescription business near-term.
02/27/18
BOFA
02/27/18
INITIATION
Target $19
BOFA
Buy
Owens & Minor reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Michael Cherny reinstated coverage on Owens & Minor with a Buy and $19 price target.
03/08/18
LEHM
03/08/18
INITIATION
Target $16
LEHM
Underweight
Owens & Minor initiated with an Underweight at Barclays
Barclays analyst Steve Valiquette started Owens & Minor with an Underweight rating and $16 price target. The analyst initiated 14 companies in Health Care Services with a Neutral industry view.
PCRX Pacira
$31.90

0.2 (0.63%)

02/21/18
BMOC
02/21/18
NO CHANGE
Target $32
BMOC
Market Perform
Pacira Q4 sales momentum 'eased a bit' in January, says BMO Capital
BMO Capital analyst Gary Nachman notes Symphony data for January were released and show sales of Pacira Pharmaceuticals' Exparel of $23.2M, up a "healthy" 12.4% year-over-year. While the sales dropped 14.3% from December, January is normally lighter than December, Nachman tells investors in an intraday research note. Sales per selling day were below the levels for all Q4, the analyst notes, which he views as more concerning than the month-over-month decline. The analyst believes "some of the Exparel momentum" in Q4 "eased a bit" in January. He keeps a Market Perform rating on Pacira with a $32 price target.
03/01/18
HCWC
03/01/18
NO CHANGE
Target $45
HCWC
Buy
Pacira price target lowered to $45 from $55 at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat lowered his price target for Pacira Pharmaceuticals to $45 after entirely removing the nerve-block indication for Exparel. The analyst, however, views the company's 2018 outlook as conservative and keeps a Buy rating on the shares.
03/01/18
RBCM
03/01/18
NO CHANGE
Target $44
RBCM
Outperform
Pacira price target lowered to $44 from $54 at RBC Capital
RBC Capital analyst Randall Stanicky lowered his price target on Pacira to $44 after Q4 earnings, saying the outlook for FY18 EXPAREL sales was below expectations. Stanicky keeps his Outperform rating on the stock, noting that the guidance is likely conservative and leaves some room for the upside in the upcoming updates.
02/16/18
LSCM
02/16/18
NO CHANGE
Target $42
LSCM
Buy
Heron gained edge with Pacira's negative panel vote, says Lake Street
Heron Therapeutics' (HRTX) HTX-011 gained an edge yesterday after an FDA advisory committee recommended not to approve Pacira Pharmaceuticals' (PCRX) proposed label expansion for Exparel, Lake Street analyst Bruce Jackson tells investors in a research note. Heron believes it has addressed the issues raised by the FDA panel with its Phase 3 study, the results for which are expected between late Q1/mid Q2, Jackson adds. The analyst keeps a Buy rating on Heron with a $42 price target.
RDUS Radius Health
$35.28

2.23 (6.75%)

01/29/18
01/29/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. PepsiCo (PEP) initiated with a Hold at SunTrust. 2. Synlogic (SYBX) initiated with an Overweight at Piper Jaffray. 3. Centennial Resource Development (CDEV) initiated with a Buy at Guggenheim. 4. Zynerba (ZYNE) initiated with a Buy at Ladenburg. 5. Radius Health (RDUS) initiated with an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/29/18
MSCO
01/29/18
INITIATION
Target $57
MSCO
Overweight
Radius Health initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison started Radius Health (RDUS) with an Overweight rating and $57 price target, contending that pricing and convenience offer a path for Radius' Tymlos to take share from market leader Forteo, sold by Eli Lilly (LLY). While Tymlos is launching well, Radius' patch development offers a path to long-term market expansion and elacestrant in breast cancer remains underappreciated by consensus, Harrison added.
01/22/18
SBSH
01/22/18
NO CHANGE
Target $43
SBSH
Neutral
Radius Health price target raised to $43 from $30 at Citi
Citi analyst Robyn Karnauskas raised her price target for Radius Health to $43 saying Tymlos new patient share is growing faster than expected. After meeting with management, the analyst says the stock's risk/reward could skew to the upside on the company's patch update or anabolic market growth. She keeps a Neutral rating on the shares.
12/06/17
SBSH
12/06/17
INITIATION
Target $30
SBSH
Neutral
Radius Health initiated with a Neutral at Citi
Citi analyst Robyn Karnauskas started Radius Health with a Neutral rating and $30 price target. The analyst believes the Tymlos launch will be the key story for 2018 and prefers to wait on the sidelines until the company's cancer program comes to the forefront.
COF Capital One
$100.79

2.64 (2.69%)

01/24/18
BMOC
01/24/18
NO CHANGE
Target $140
BMOC
Outperform
Capital One price target raised to $140 from $134 at BMO Capital
BMO Capital analyst James Fotheringham raised his price target on Capital One (COF) to $140, saying the company's "growth math" on earnings can transition from a headwind to a tailwind this year on benefits of the U.S. tax reform and Cabela's (CAB) loans acquisition. The analyst maintains that he is bullish on banks this year, and Capital One is his "highest conviction investment recommendation". Fotheringham keeps his Outperform rating on the stock.
01/24/18
WELS
01/24/18
NO CHANGE
Target $117
WELS
Outperform
Capital One price target raised to $117 from $112 at Wells Fargo
Wells Fargo analyst Donald Fandetti raised his price target for Capital One to $117 from $112 following quarterly results. The analyst reiterates an Outperform rating on the shares.
02/21/18
NOMU
02/21/18
DOWNGRADE
Target $109
NOMU
Neutral
Capital One downgraded to Neutral from Buy at Nomura Instinet
Nomura Instinet analyst Bill Carcache downgraded Capital One Financial to Neutral and lowered his price target for the shares to $109 from $111. The analyst believes the benefit of improving credit is now fully discounted in the shares and he sees "little room" for positive earnings revisions given the company's slowing sales growth.
02/21/18
02/21/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Capital One (COF) downgraded to Neutral from Buy at Nomura Instinet with analyst Bill Carcache saying he believes the benefit of improving credit is now fully discounted in the shares and he sees "little room" for positive earnings revisions given the company's slowing sales growth. 2. Lionsgate (LGF.A, LGF.B) downgraded to Market Perform from Outperform at Bernstein with analyst Todd Juenger saying he believes competitive investment from rival premium and SVOD services has gotten much more intense, and notes that increased programming investment at Starz is a necessary but recurring cost of doing business, which means the normalized growth rate for Starz has to be lower. 3. Match Group (MTCH) downgraded to Neutral from Overweight at JPMorgan with analyst Doug Anmuth saying he sees fewer catalysts in the first half of 2018 now that the surge in Tinder Gold has passed. 4. BHP Billiton (BHP) downgraded to Neutral from Buy at Citi with analyst Heath Jansen saying the company's first half of fiscal 2018 results were below expectations. 5. Regeneron (REGN) downgraded to Hold from Buy at Canaccord with analyst John Newman citing concern over the company's decision to not provide guidance for Eylea, which is concerning because it will remain the company's core revenue component for many years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CAH Cardinal Health
$71.16

0.74 (1.05%)

01/04/18
EVER
01/04/18
INITIATION
Target $67
EVER
In Line
Cardinal Health initiated with an In Line at Evercore ISI
Evercore ISI started Cardinal Health with an In Line rating and $67 price target.
02/27/18
BOFA
02/27/18
INITIATION
Target $69
BOFA
Underperform
Cardinal Health reinstated with an Underperform at BofA/Merrill
BofA/Merrill analyst Michael Cherny reinstated coverage on Cardinal Health with an Underperform and $69 price target.
03/08/18
LEHM
03/08/18
INITIATION
Target $74
LEHM
Equal Weight
Cardinal Health initiated with an Equal Weight at Barclays
Barclays analyst Steve Valiquette started Cardinal Health with an Equal Weight rating and $74 price target. The analyst initiated 14 companies in Health Care Services with a Neutral industry view.
SNN Smith & Nephew
$37.53

0.29 (0.78%)

01/25/18
JPMS
01/25/18
UPGRADE
JPMS
Overweight
Smith & Nephew upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst David Adlington upgraded Smith & Nephew to Overweight and raised his price target for the shares to GBP 14.11 from GBP 13.69.
12/11/17
MSCO
12/11/17
DOWNGRADE
MSCO
Equal Weight
Smith & Nephew downgraded to Equal Weight from Overweight at Morgan Stanley
10/11/17
ADAM
10/11/17
INITIATION
Target $42
ADAM
Buy
Smith & Nephew initiated with a Buy at Canaccord
Canaccord analyst Kyle rose initiated Smith & Nephew with a Buy as he believes its broad product portfolio provides a stronger foundation from which the company can realize accelerating top-line growth. He said its recent restructuring has positioned it to focus on commercial execution and operating leverage. Rose has a $42 price target on Smith & Nephew shares.
03/21/17
03/21/17
UPGRADE
Target $36

Buy
Wright Medical upgraded on increased likelihood of a takeout at Northcoast
As previously reported, Northcoast upgraded Wright Medical (WMGI) to Buy from Neutral with a $36 price target. Analyst David Kaiser said he has been slow to appreciate Wright's competitive advantages in the extremity market and believes a takeout is increasingly likely in 2017. The analyst attended last week's American Academy of Orthopedic Surgeons annual meeting and said multiple private industry contacts told him there is increased speculation in the market about one of the four major joint replacement manufacturers acquiring Wright Medical soon. Kaiser believes Smith & Nephew (SNN) is the most logical acquirer given it has virtually no presence in the extremity market, has a very strong balance sheet, and a clear strategy to shift its business mix to faster-growing areas.
SNE Sony
$51.40

0.12 (0.23%)

11/17/17
RILY
11/17/17
NO CHANGE
Target $36
RILY
Neutral
21st Century Fox price target raised to $36 from $29 at B. Riley FBR
B. Riley FBR analyst Barton Crockett raised his price target for 21st Century Fox (FOXA) to $36 citing recent reports that Disney (DIS), Comcast (CMCSA), Verizon (VZ) or Sony (SNE) may make offers for the company. The "formerly unthinkable" prospect of Rupert Murdoch selling assets is likely to be factored into the equity price for some time, Crockett tells investors in a research. He keeps a Neutral rating on Fox given the stock's proximity to his new target.
12/07/17
BARD
12/07/17
NO CHANGE
BARD
Data so far suggesting healthy holiday game sales, says Baird
Baird analyst Colin Sebastian noted that French game maker Ubisoft (UBSFY) raised its revenue and margin guidance for the December quarter, which he views as a slight positive for video game industry sales momentum this holiday season. Data also point to solid sales for both Sony's (SNE) PS4 and Nintendo's (NTDOY) Switch, which are a driver of software as well as a key catalyst for Gamestop (GME), Sebastian added. Other publicly traded companies in the video game space include Activision Blizzard (ATVI), Electronic Arts (EA), Take-Two (TTWO) and Microsoft (MSFT).
01/23/18
JPMS
01/23/18
DOWNGRADE
JPMS
Neutral
Sony downgraded to Neutral from Overweight at JPMorgan
01/23/18
01/23/18
DOWNGRADE

Neutral
Sony downgraded to Neutral on slowing dual-cam adoption at JPMorgan
As previously reported, JPMorgan downgraded Sony (SNE) to Neutral from Overweight, citing slowing adoption of dual-cams. The firm notes that reports indicate Apple's (AAPL) iPhone 6.05" LCD model will not have a dual-cam feature, which it sees presenting a material downside risk in dual-camera adoption in the second half of 2018.
MDT Medtronic
$83.15

0.94 (1.14%)

02/26/18
PIPR
02/26/18
NO CHANGE
Target $60
PIPR
Overweight
Medtronic news incremental negative for Dexcom, says Piper Jaffray
Medtronic (MDT) this morning announced it received a new arm indication for its Guardian Sensor 3 which improves the accuracy of the sensor to an 8.7% MARD, likely leading to a non-adjunctive claim for standalone, Piper Jaffray analyst JP McKim tells investors in a research note. The news is an incremental negative for Dexcom (DXCM) shares as a path to non-adjunctive claim for Medtronic has become much clearer, McKim contends. He expects a stand-alone launch of Guardian Sensor 3 sometime in 2018. The analyst believes Dexcom carries more negative headline risk in the near term, but he expects the company to remain the market leader in continuous glucose monitors. As such, McKim thinks longer term investors should be buying the stock. He keeps an Overweight rating on Dexcom with a $60 price target. The stock in morning trading is down 12c to $56.24.
01/18/18
PIPR
01/18/18
NO CHANGE
Target $82
PIPR
Overweight
Insulet is a favored diabetes play on business momentum, says Piper Jaffray
Piper Jaffray analyst JP McKim says he hosted calls yesterday with two Certified Diabetes Educators from a "high volume center" and learned that they expect Continuous Glucose Monitoring - CGM - to become a "standard of care" in the Type 1 market, which can reach penetration of 85% vs 40% today. The analyst says the findings support his view that CGM is set for accelerating growth. Kim also notes that the impact on Medtronic (MDT) is improving, while the business momentum at Insulet (PODD) continues. The analyst rates Insulet as his top choice, followed by Dexcom (DXCM) and Tandem Diabetes Care (TNDM) in the space, given the headline risk around Libre coverage and insufficient evidence of accelerating pump additions for the latter names respectively. Kim keeps his Overweight rating and $82 price target on Insulet.
CNMD CONMED
$63.31

1.15 (1.85%)

04/27/17
NEED
04/27/17
NO CHANGE
Target $54
NEED
Buy
CONMED price target raised to $54 from $48 at Needham
Needham analyst Mike Matson raised his price target for CONMED to $54 from $48 after the company's Q1 revenue and EPS beat consensus and management maintained its 2017 guidance. The analyst is encouraged by the improvement in revenue growth and reiterates a Buy rating, though he needs to see it sustained for a few more quarters before he is comfortable declaring the CONMED turnaround a success.
02/01/18
NEED
02/01/18
NO CHANGE
Target $71
NEED
Buy
CONMED price target raised to $71 from $58 at Needham
Needham analyst Mike Matson raised his price target on CONMED to $71 and kept his Buy rating after Q4 earnings beat. The analyst says the company has "finally turned around its US Orthopedics business which was the one remaining drag on its growth". Matson also cites the management's forecast of sustaining mid-single digit revenue growth and double-digit EPS growth, which he adds may prove to be conservative.
04/27/17
LEER
04/27/17
NO CHANGE
Target $52
LEER
Market Perform
CONMED price target raised to $52 from $45 at Leerink
Leerink analyst Richard Newitter raised his price target for CONMED to $52 from $45 after the company delivered a "good Q1" with revenue/EPS ahead of expectations. The analyst reiterates a Market Perform rating on the shares.
ENDP Endo
$6.98

-0.1 (-1.41%)

02/28/18
GABE
02/28/18
DOWNGRADE
GABE
Hold
Endo downgraded to Hold at Gabelli on soft FY18 outlook
As reported earlier, Gabelli analyst Kevin Kedra downgraded Endo International to Hold from Buy after the company's below-consensus FY18 outlook. Kedra also points to some $8.4B in debt looming over the company as its ability to reduce the burden is restricted by its multiple cash warnings as well as the absence of near-term catalysts.
02/28/18
GABE
02/28/18
DOWNGRADE
GABE
Hold
Endo downgraded to Hold from Buy at Gabelli
02/26/18
LEER
02/26/18
NO CHANGE
LEER
Outperform
Potential settlement on Testosterone step in right direction for Endo, says Leerink
Leerink analyst Ami Fadia notes that in the Multidistrict Litigation 2545 regarding Testosterone Replacement Therapy Products Liability Litigation, the parties involved including Endo entered into a Memorandum of Understanding on a potential global settlement. While the analyst acknowledges that investors remain cautious on the ultimate financial impact of the mesh liabilities, she believes this is another step in the right direction that Endo is taking to put the overhang from litigation proceedings behind it. Fadia thinks that as management moves to settle pending litigation, this will shift focus back to the operational aspects of the company, which are "underappreciated."
02/26/18
JMPS
02/26/18
DOWNGRADE
JMPS
Market Perform
Endo downgraded to Market Perform from Outperform at JMP Securities
JMP Securities analyst Donald Ellis downgraded Endo to Market Perform from Outperform, stating that the company has a consistently declining branded base business and base generics business and he believes it has been very difficult for Endo to deleverage its balance sheet. Ellis downgraded the stock to Market Perform as his final rating, as JMP is terminating coverage of Endo International to reallocate research resources.
MDXG MiMedx
$7.42

-0.5 (-6.31%)

02/27/18
CHLM
02/27/18
NO CHANGE
Target $19
CHLM
Buy
Craig-Hallum maintains Buy rating, $19 price target on MiMedx
Craig-Hallum analyst Matt Hewitt noted that MiMedx denied a report that it is under investigation by the Department of Justice, stating that it is not aware of any such investigation. While stating that "it is impossible to know for certain whether any nefarious activity has ever taken place at MiMedx," Hewitt points to several events over the past year that give him confidence in the integrity of the company's financials. If the company's financials are sound, he estimate that the stock is worth two and a half times the current price, added Hewitt, who keeps a Buy rating and $19 price target on MiMedx shares.
02/23/18
LSCM
02/23/18
DOWNGRADE
LSCM
Hold
MiMedx downgraded to Hold from Buy at Lake Street
02/23/18
CHLM
02/23/18
NO CHANGE
Target $19
CHLM
Buy
MiMedx fundamentals, execution should ultimately 'win out,' says Craig-Hallum
Craig-Hallum analyst Matt Hewitt noted that MiMedx management hosted an update call to address investor concerns about the recently announced investigation into sales practices and accounting, during which they revealed that King & Spalding has been hired as an independent legal advisor and KPMG will provide forensic accounting services. Uncertainty surrounding the investigation and recent short seller attacks have pushed shares over 50% off of their highs, but Hewitt ultimately thinks the company's fundamentals and strong execution will "win out," making the stock "intriguing" at current levels, he tells investors. He keeps a Buy rating and $19 price target on MiMedx shares.
02/23/18
02/23/18
DOWNGRADE
Target $9

Hold
MiMedx downgraded to Hold with $9 price target at Lake Street
As previously reported, Lake Street analyst Bruce Jackson downgraded MiMedx to Hold from Buy, stating that a resolution of the investigation into current and prior period sales and distribution practices is unlikely to be swift and the shares are unlikely to outperform until the investigation is resolved. If the investigation resolves favorably, the upside potential "would be significant and he would be an aggressive buyer of the stock, but for now Jackson cut his price target on MiMedx shares to $9 from $12.
WMGI Wright Medical
$20.67

0.13 (0.63%)

01/08/18
PIPR
01/08/18
NO CHANGE
Target $32
PIPR
Overweight
Piper recommends Wright Medical after preliminary Q4 results
Piper Jaffray analyst Matt O'Brien recommends investors purchase shares of Wright Medical following this morning's preliminary Q4 results. Wright reported preliminary Q4 revenue that beat consensus estimates, and importantly, 2017 sales came in at the high end of previously provided guidance range, O'Brien tells investors in a research note. The analyst sees a "solid set-up" for 2018 and keeps an Overweight rating on Wright Medical with a $32 price target.
01/04/18
CANT
01/04/18
INITIATION
Target $30
CANT
Overweight
Wright Medical assumed with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald assumed coverage of Wright Medical with an Overweight rating and $30 price target.
10/09/17
10/09/17
NO CHANGE

Valuations in Medical Technology look more attractive, says RBC Capital
RBC Capital analyst Glenn Novarro says the recent pullback in Medical Technology stocks since Q2 earnings has eliminated the valuation gap relative to other S&P Health Care subsectors. The analyst recommends a "Buy Now" for Johnson & Johnson (JNJ) and "Buy on Weakness" for Abbott Laboratories (ABT) among diversified MedTech names. In Cardiovascular, Novarro says "Buy Now" for Edwards Lifesciences (EW) and "Buy on Weakness" for Boston Scientific (BSX). For Nuvasive (NUVA) and Wright Medical (WMGI), the analyst says management will cut guidance because of hurricane related revenue shortfalls, but the selloff over the past several weeks is already discounting those expectations.
VCEL Vericel
$11.55

-0.25 (-2.12%)

03/05/18
PIPR
03/05/18
NO CHANGE
Target $14
PIPR
Overweight
Vericel price target raised to $14 from $9 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Vericel to $14 after Maci sales in Q4 topped expectations. The analyst views Vericel's Q4 results as solid and looks for continued growth in 2018. He keeps an Overweight rating on the shares.
03/06/18
NEED
03/06/18
NO CHANGE
Target $15
NEED
Buy
Vericel price target raised to $15 from $5 at Needham
Needham analyst Chad Messer raised his price target on Vericel to $15 after the company's Q4 results, which marked a 3rd straight quarter of above 20% revenue growth. Messer adds that the company's margins were also stronger amid higher volumes relative to Vericel's fixed cost base. The analyst keeps his Buy rating on Vericel, stating that its MACI product addresses an under-penetrated market and gives this company, which has the cash to reach profitability, "substantial momentum" in 2018.
03/06/18
LTCO
03/06/18
DOWNGRADE
LTCO
Neutral
Vericel downgraded to Neutral from Buy at Ladenburg
01/02/18
PIPR
01/02/18
NO CHANGE
Target $9
PIPR
Overweight
Vericel price target raised to $9 from $7 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Vericel to $9 after the company received $5.1M from Chinese partner ICT. The analyst expects "healthy" MACI sales growth to drive value and reiterates an Overweight rating on Vericel.

TODAY'S FREE FLY STORIES

FNWB

First Northwest Bancorp

$16.11

0.36 (2.29%)

17:48
07/20/18
07/20
17:48
07/20/18
17:48
Hot Stocks
First Northwest Bancorp names Terry Anderson chief credit officer »

First Northwest Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$15.75

-0.05 (-0.32%)

17:42
07/20/18
07/20
17:42
07/20/18
17:42
Hot Stocks
Freeport McMoRan CAO Michael Arnold to retire »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$74.87

-0.24 (-0.32%)

, XLU

Utilities SPDR

$52.28

-0.39 (-0.74%)

17:39
07/20/18
07/20
17:39
07/20/18
17:39
General news
Week ending ETF Scorecard: Financials lead, Energy slumps »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$74.87

-0.24 (-0.32%)

XLU

Utilities SPDR

$52.28

-0.39 (-0.74%)

IYR

DJ US Real Estate Index Fund

$80.23

-0.68 (-0.84%)

XLP

Consumer Staples Sector SPDR

$52.84

0.3 (0.57%)

XLY

Consumer Discretionary Sector SPDR

$112.15

-0.47 (-0.42%)

XLB

S&P Select Materials SPDR

$58.31

-0.21 (-0.36%)

XLF

Financial Select Sector

$27.57

0.065 (0.24%)

XLV

Health Care Select Sector SPDR

$86.74

-0.17 (-0.20%)

XLK

Technology Select Sector SPDR

$72.55

0.01 (0.01%)

XLI

Industrial Select Sector SPDR

$74.44

-0.09 (-0.12%)

GLD

SPDR Gold Trust

$116.56

0.74 (0.64%)

SLV

iShares Silver Trust

$14.59

0.18 (1.25%)

USO

United States Oil Fund

$14.15

0.025 (0.18%)

UNG

United States Natural Gas Fund

$22.38

-0.06 (-0.27%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.62

0.03 (0.04%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.27

-0.335 (-0.29%)

TLT

iShares 20+ Year Treasury Bond Fund

$120.78

-1.46 (-1.19%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.21

-0.35 (-0.34%)

SHY

iShares 1-3 Year Treasury Bond

$83.26

-0.005 (-0.01%)

IWD

iShares Russell 1000 Value

$123.07

-0.2897 (-0.23%)

IWF

iShares Russell 1000 Growth

$149.41

-0.04 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRX

Xerox

$25.10

-0.095 (-0.38%)

, FUJIY

Fujifilm

$0.00

(0.00%)

17:25
07/20/18
07/20
17:25
07/20/18
17:25
Hot Stocks
Xerox, Centerview settle matters related to proposed Fuji tie-up »

On July 20, 2018, Xerox…

XRX

Xerox

$25.10

-0.095 (-0.38%)

FUJIY

Fujifilm

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

STON

StoneMor Partners

$3.61

-0.015 (-0.41%)

17:15
07/20/18
07/20
17:15
07/20/18
17:15
Hot Stocks
Breaking Hot Stocks news story on StoneMor Partners »

Oaktree Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEF

Telefonica

$8.70

0.07 (0.81%)

17:11
07/20/18
07/20
17:11
07/20/18
17:11
Downgrade
Telefonica rating change  »

Telefonica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

, USO

United States Oil Fund

$14.15

0.025 (0.18%)

17:04
07/20/18
07/20
17:04
07/20/18
17:04
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 5.5K…

SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

USO

United States Oil Fund

$14.15

0.025 (0.18%)

GLD

SPDR Gold Trust

$116.56

0.74 (0.64%)

FXE

Euro Currency Trust

$112.46

0.83 (0.74%)

FXC

CurrencyShares Canadian Dollar Trust

$75.17

0.81 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZWI

Citizens Community Bancorp

$14.15

(0.00%)

17:02
07/20/18
07/20
17:02
07/20/18
17:02
Syndicate
Breaking Syndicate news story on Citizens Community Bancorp »

Citizens Community…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PKD

Parker Drilling

$0.30

-0.0044 (-1.46%)

17:01
07/20/18
07/20
17:01
07/20/18
17:01
Hot Stocks
Breaking Hot Stocks news story on Parker Drilling »

Whitebox Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

RSLS

ReShape Lifesciences

$1.47

-0.02 (-1.34%)

17:00
07/20/18
07/20
17:00
07/20/18
17:00
Hot Stocks
Breaking Hot Stocks news story on ReShape Lifesciences  »

Intracoastal Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOX

Box

$26.13

-0.26 (-0.99%)

16:57
07/20/18
07/20
16:57
07/20/18
16:57
Initiation
Box initiated  »

Box initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDX

Aldeyra

$7.95

-0.15 (-1.85%)

16:53
07/20/18
07/20
16:53
07/20/18
16:53
Syndicate
Breaking Syndicate news story on Aldeyra »

Aldeyra files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLRE

Greenlight Capital Re

$14.00

-0.15 (-1.06%)

16:46
07/20/18
07/20
16:46
07/20/18
16:46
Hot Stocks
Greenlight Capital Re announces departure of COO »

Greenlight Capital Ry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RVI

Retail Value

$34.56

0.2 (0.58%)

16:38
07/20/18
07/20
16:38
07/20/18
16:38
Hot Stocks
Breaking Hot Stocks news story on Retail Value »

Luxor Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LECO

Lincoln Electric

$92.26

0.64 (0.70%)

, ROK

Rockwell Automation

$171.32

-0.71 (-0.41%)

16:35
07/20/18
07/20
16:35
07/20/18
16:35
Hot Stocks
Lincoln Electric expands board to 11 directors, appoints Patrick Goris to board »

Lincoln Electric (LECO)…

LECO

Lincoln Electric

$92.26

0.64 (0.70%)

ROK

Rockwell Automation

$171.32

-0.71 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Jul

KMX

CarMax

$77.15

-0.57 (-0.73%)

16:33
07/20/18
07/20
16:33
07/20/18
16:33
Hot Stocks
CarMax chairman sells 37,500 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$100.65

-0.74 (-0.73%)

16:31
07/20/18
07/20
16:31
07/20/18
16:31
Hot Stocks
Lowe's names Joseph McFarland as EVP of stores »

Lowe's Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
07/20/18
07/20
16:30
07/20/18
16:30
Options
Preliminary option volume of 20.2M today »

Preliminary option volume…

PFE

Pfizer

$37.33

-0.03 (-0.08%)

16:26
07/20/18
07/20
16:26
07/20/18
16:26
Hot Stocks
FDA approves Pfizer's Biosimilar NIVESTYM for all indications »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

JCP

J.C. Penney

$2.50

-0.065 (-2.53%)

16:23
07/20/18
07/20
16:23
07/20/18
16:23
Hot Stocks
J.C. Penney chief customer officer McFarland to leave company »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
07/20/18
07/20
16:20
07/20/18
16:20
Options
Closing CBOE SPX and VIX Index summary for July 20th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASFI

Asta Funding

$3.15

-0.1 (-3.08%)

16:18
07/20/18
07/20
16:18
07/20/18
16:18
Hot Stocks
Asta Funding receives Nasdaq non-compliance letter »

Asta Funding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
07/20/18
07/20
16:17
07/20/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
07/20/18
07/20
16:16
07/20/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

16:15
07/20/18
07/20
16:15
07/20/18
16:15
Periodicals
Disney fires 'Guardians' director after controversial tweets, THR says »

Disney has fired James…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.